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Abstract
Mul$ple Sclerosis (MS) is an inﬂammatory demyelina$on disease of the central nervous system that results in debilita$ng symptoms such as muscle spasms, muscle s$ﬀness, loss of coordina$on, change and loss in sensa$on,
change in bowel and bladder func$on, and vision loss. It can take four diﬀerent disease pathways and can progress at diﬀerent rates, but all will eventually disable the pa$ent. Medica$on can be used for acute ﬂare-ups, but when
it comes to maintenance or progression therapy, there is very liCle to oﬀer MS pa$ents. Physical therapy has proven to help maintain muscle strength, but there are limita$ons to its beneﬁts, as there is no evidence that it will
improve muscle weakness or spas$city. Therefore this review will analyze the use of electrical s$mula$on in combina$on with physical therapy and pose the ques$on; In pa$ents between the ages of 20 and 60 with progressive
mul$ple sclerosis (P), does the use of func$onal electrical s$mula$on in conjunc$on with physical therapy (I) reduce established gait impairment (O) beCer than physical therapy alone (C)?

Results

Discussion

The 6 outcome measurements that are seen in the table below were
considered together to determine the eﬃcacy of FES and PT as a
treatment of gait impairment.
• Four of the ar$cles found improvement in mean walking speed and
three of the six found improvement in motor func$on.
• There was no signiﬁcant improvement of mean walking distance or
physiologic cost on the body in any of the studies.
• One study found an overall improvement in MS disease ra$ng.
Although none of the studies found successful treatment of FES in the
exact same categories as another, each showed that there was
signiﬁcant improvement in some aspect of gait func$on with the use of
or addi$on of FES.

Every ar$cle found signiﬁcant improvement of at least one outcome
measurement used to determine an improvement of gait func$on
with the use of FES. The ar$cles were slightly diﬃcult to compare,
as the pa$ent popula$ons varied over the six ar$cles. Each ar$cle
used pa$ents with progressive MS, but the exact level of disability
of the par$cipants diﬀered among the studies. Five of the six
ar$cles were designed as RCTs and one as a cohort study, all of
which allowed for op$mal inves$ga$on of FES as a treatment
method. Three of the six ar$cles compare FES and PT directly rather
than in combina$on, which gives us further informa$on on
treatment eﬃcacy individually, but leaves room for further
inves$ga$on of a combined modality therapy. Overall weaknesses
of the studies are seen in Table 2.

IntroducCon
Myelin Sheath: a protec$ve layer surrounding nerves in the body that allows for
signals to be transmiCed quickly and suﬃciently throughout the body
• Mul$ple Sclerosis is an inﬂammatory disease that breaks down this layer
leaving the pa$ent with faulty brain-body signal transmission leading to many
debilita$ng symptoms
Four clinical subtypes of MS:
• Relapsing remiTng MS (RRMS)
• Primary progressive MS (PPMS)
• Secondary progressive MS (SPMS)
• Progressive-relapsing MS(PRMS)
PopulaCon aﬀected: approximately 2 million people around the world, typically
diagnosed between the ages of 20 and 50. Due to the progressive nature of the
disease, all with experience a myriad of symptoms within a decade of diagnosis.
Treatment:
• Pharmacologic treatment is limited to controlling acute ﬂares and aCemp$ng
to prevent future ﬂares but does very liCle for daily symptoma$c control
• Physical therapy (PT) is shown to help maintain the muscle strength pa$ents
currently possess, but does liCle to improve it
• Func$onal electrical s$mula$on (FES) has shown to be eﬀec$ve in aiding
pa$ents with similar neurological deﬁcits maintain and improve their level of
func$oning in order to achieve normal ac$vi$es of daily life

Methods
• Literature search in November 2018 using:
• PubMed
• Google Scholar
• EBSCO
• Academic Search Ul$mate
• Key words used: “progressive mul$ple sclerosis or ms” and “func$onal
electrical s$m*”
• Exclusion criteria:
• Studies including pa$ents under 20 or over 60
• Studies published prior to 2008
• Studies that included physical therapy focused on the upper limbs

Table 1. Comparison of Results

Study Mean Mean
Improveme Foot
Walking Walking nt of Motor Drop
Speed Distance FuncCon

Physiologic MS
Cost on the disease
Body
raCng
improve
ment

BarreC FES: S
et al
PT: S
(2009)
Hammon N/A
d et al
(2015)

FES: NS
PT: NS

N/A

N/A

FES: NS
PT: NS

N/A

N/A

FES: S
PT:NS

N/A

N/A

FES: NS
PT: NS

Raﬀerty N/A
et al
(2008)
Taylor et FES: S
al (2014) PT: NS

N/A

FES: S
PT: N/A

N/A

N/A

FES: NS
PT: N/S

N/A

N/A

N/A

FES: NS
PT: NS

N/A

Tyler et FES: S
al (2014) PT: NS

N/A

FES: S
PT: NS

N/A

FES: NS
PT: NS

FES: S
PT: NS

N/A

FES: S
PT:N/A

N/A

N/A

Van der FES: S
FES: NS
Linden PT: N/A PT: N/A
et al
(2014)

Key: S=Sta$s$cally Signiﬁcant, NS=Not Sta$s$cally Signiﬁcant, N/A=Not applicable
to the study, FES = Func$onal Electrical S$mula$on, PT = Physical Therapy

Table 2. Overall Study Weaknesses
Weakness

Small sample size

Short study
duraCon
Largest study included
All RCT studies
only 53 par$cipants, with were carried out
the smallest including 9
in 30 weeks or
par$cipants
less, with no
long-term follow
up

Varied FES administraCon
methods

Diﬀering methods
included:
• peroneal nerve
s$mula$on
• gluteal s$mula$on
• glosseal s$mula$on

Conclusion
The six studies chosen show that FES as a therapy, while not
proven to be more beneﬁcial in all aspects of analysis, provides
some superior beneﬁts to gait func$on improvement over physical
therapy alone. The studies themselves were not perfect, and at
the moment there is not enough evidence to say conclusively that
FES should become a standard of care when it comes to MS
treatment. Further research needs to be done in order to
inves$gate the long term eﬀects of FES on gait disturbance in those
suﬀering from MS. Short term improvement does not necessarily
correlate to long term regression of symptoms.
Overall, this research has shown that FES has deﬁniCve promise
in the treatment of the debilitaCng symptoms of MS, but further
invesCgaCon is needed.

